Logo
x

Search

Subscribe Now

associated

BioXcel's BXCL501 Receives the US FDA's Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia

BioXcel's BXCL501 Receives the US FDA's Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia

  • March 15, 2021
Jazz Pharmaceuticals' Xywav (calcium- magnesium- potassium- and sodium oxybates) Receives the US FDA's Approval for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals' Xywav (calcium- magnesium- potassium- and sodium oxybates) Receives the US FDA's Approval for Cataplexy or E...

  • July 22, 2020
Angion Commences P-II Study of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia in Brazil

Angion Commences P-II Study of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia in Brazil

  • July 8, 2020
Zogenix's Fintepla (fenfluramine) Receives the US FDA's Approval for the Treatment of Seizures Associated with Dravet Syndrome

Zogenix's Fintepla (fenfluramine) Receives the US FDA's Approval for the Treatment of Seizures Associated with Dravet Syndrome

  • June 26, 2020
Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated with COVID-19

Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated wit...

  • June 25, 2020
GSK to Evaluate Otilimab for Treating Pulmonary Disease Associated with COVID-19

GSK to Evaluate Otilimab for Treating Pulmonary Disease Associated with COVID-19

  • May 8, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.